Free Trial
→ Trump’s Bitcoin Reserve is No Accident… (From Crypto 101 Media) (Ad) Buy GMRE Stock  Free GMRE Stock Alerts

Global Medical REIT (GMRE) Financials

Global Medical REIT logo
$6.16 +0.01 (+0.08%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Global Medical REIT

Annual Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 0.81 15 13
Consolidated Net Income / (Loss)		 6.69 22 20
Net Income / (Loss) Continuing Operations		 4.20 7.04 13
Total Pre-Tax Income 		4.20 7.04 13
Total Revenue		 110 110 112
Net Interest Income / (Expense)		 -29 -31 -25
Total Interest Income		 0.00 0.00 0.00
Total Interest Expense		 29 31 25
Long-Term Debt Interest Expense		 29 31 25
Total Non-Interest Income		 139 141 137
Other Service Charges		 0.37 0.12 0.12
Other Non-Interest Income		 138 141 137
Total Non-Interest Expense		 106 103 99
Other Operating Expenses		 50 45 42
Depreciation Expense		 40 41 40
Amortization Expense		 15 17 17
Restructuring Charge		 0.16 0.04 0.35
Other Gains / (Losses), net		 -1.72 -0.87 0.00
Net Income / (Loss) Discontinued Operations		 4.21 16 6.75
Preferred Stock Dividends Declared		 5.82 5.82 5.82
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.06 1.12 0.85
Basic Earnings per Share		 $0.01 $0.23 $0.20
Weighted Average Basic Shares Outstanding		 65.94M 65.55M 65.46M
Diluted Earnings per Share		 $0.01 $0.23 $0.20
Weighted Average Diluted Shares Outstanding		 65.94M 65.55M 65.46M
Weighted Average Basic & Diluted Shares Outstanding		 66.87M 65.57M 65.53M
Cash Dividends to Common per Share		 $0.84 $0.84 $0.84

Quarterly Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 1.37 1.79 -3.15 0.79 -0.84 3.14 12 0.67 0.37 8.06
Consolidated Net Income / (Loss)		 2.94 3.39 -1.95 2.31 0.55 4.83 14 2.17 1.85 10
Net Income / (Loss) Continuing Operations		 -1.11 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
Total Pre-Tax Income 		-1.11 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
Total Revenue		 28 27 27 28 26 28 28 28 28 28
Net Interest Income / (Expense)		 -7.57 -7.24 -6.99 -6.89 -6.98 -7.17 -8.47 -8.27 -8.07 -6.96
Total Interest Expense		 7.57 7.24 6.99 6.89 6.98 7.17 8.47 8.27 8.07 6.96
Long-Term Debt Interest Expense		 7.57 7.24 6.99 6.89 6.98 7.17 8.47 8.27 8.07 6.96
Total Non-Interest Income		 35 34 34 35 33 36 36 36 36 35
Other Service Charges		 0.21 0.09 0.03 0.05 0.03 0.02 0.03 0.03 0.02 0.06
Other Non-Interest Income		 35 34 34 35 33 35 36 36 36 35
Total Non-Interest Expense		 29 25 26 26 25 26 26 26 26 25
Other Operating Expenses		 15 12 12 12 10 12 12 11 11 11
Depreciation Expense		 10 9.99 10 10 10 10 10 10 11 10
Amortization Expense		 3.45 3.65 3.87 3.97 4.04 4.10 4.34 4.40 4.51 4.29
Restructuring Charge		 0.16 0.00 0.00 0.00 - 0.00 0.00 0.04 0.11 0.11
Net Income / (Loss) Discontinued Operations		 5.77 1.82 -3.38 0.00 - 2.29 13 0.49 - 6.75
Preferred Stock Dividends Declared		 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.11 0.15 -0.26 0.07 -0.07 0.24 0.90 0.05 0.02 0.52
Basic Earnings per Share		 $0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Weighted Average Basic Shares Outstanding		 65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Diluted Earnings per Share		 $0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Weighted Average Diluted Shares Outstanding		 65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Weighted Average Basic & Diluted Shares Outstanding		 66.87M 66.80M 65.59M 65.59M 65.57M 65.56M 65.56M 65.53M 65.53M 65.52M

Annual Cash Flow Statements for Global Medical REIT

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 2.22 -7.73 1.70
Net Cash From Operating Activities		 70 68 77
Net Cash From Continuing Operating Activities		 70 68 77
Net Income / (Loss) Continuing Operations		 6.69 22 20
Consolidated Net Income / (Loss)		 6.69 22 20
Depreciation Expense		 40 41 40
Amortization Expense		 18 20 20
Non-Cash Adjustments to Reconcile Net Income		 2.99 -8.99 -1.58
Changes in Operating Assets and Liabilities, net		 2.04 -5.69 -1.74
Net Cash From Investing Activities		 -46 68 -137
Net Cash From Continuing Investing Activities		 -46 68 -137
Purchase of Investment Securities		 -103 -11 -156
Sale and/or Maturity of Investments		 57 79 18
Other Investing Activities, net		 0.00 0.00 1.00
Net Cash From Financing Activities		 -22 -144 62
Net Cash From Continuing Financing Activities		 -22 -144 62
Net Change in Deposits		 0.25 7.16 -1.97
Issuance of Debt		 144 83 139
Issuance of Common Equity		 11 0.00 9.90
Repayment of Debt		 -111 -169 -20
Payment of Dividends		 -66 -65 -64
Cash Interest Paid		 27 30 22

Quarterly Cash Flow Statements for Global Medical REIT

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 1.15 -0.03 0.01 1.08 -0.89 -2.17 -4.20 -0.47 0.86 -0.61
Net Cash From Operating Activities		 21 16 19 14 18 17 18 16 18 18
Net Cash From Continuing Operating Activities		 21 16 19 14 18 17 18 16 18 18
Net Income / (Loss) Continuing Operations		 2.94 3.39 -1.95 2.31 0.55 4.83 14 2.17 1.85 10
Consolidated Net Income / (Loss)		 2.94 3.39 -1.95 2.31 0.55 4.83 14 2.17 1.85 10
Depreciation Expense		 10 9.99 10 10 10 10 10 10 11 10
Amortization Expense		 4.26 4.39 4.58 4.68 4.79 4.87 5.19 5.27 5.38 5.06
Non-Cash Adjustments to Reconcile Net Income		 -3.44 -0.61 5.61 1.44 3.11 -0.86 -11 0.22 1.15 -5.54
Changes in Operating Assets and Liabilities, net		 6.57 -0.86 0.57 -4.25 -0.54 -2.27 -0.50 -2.38 -0.65 -1.36
Net Cash From Investing Activities		 -20 -25 1.79 -2.72 -3.11 5.66 62 3.09 -1.41 -33
Net Cash From Continuing Investing Activities		 -20 -25 1.79 -2.72 -3.11 5.66 62 3.09 -1.41 -33
Purchase of Investment Securities		 -59 -36 -5.21 -2.55 -4.11 -3.86 -2.53 -0.81 -1.89 -53
Sale and/or Maturity of Investments		 38 12 7.49 -0.17 1.00 9.53 64 4.05 0.17 18
Other Investing Activities, net		 1.25 -0.75 -0.50 0.00 - - 0.15 -0.15 0.30 1.49
Net Cash From Financing Activities		 0.15 9.16 -21 -10 -16 -25 -84 -19 -16 15
Net Cash From Continuing Financing Activities		 0.15 9.16 -21 -10 -16 -25 -84 -19 -16 15
Net Change in Deposits		 0.02 -0.02 0.31 -0.06 8.20 -0.14 -0.26 -0.64 -0.57 -0.44
Issuance of Debt		 61 44 25 14 45 14 12 13 12 35
Repayment of Debt		 -44 -30 -29 -8.03 -53 -22 -80 -15 -11 -3.53
Payment of Dividends		 -17 -16 -16 -16 -16 -16 -16 -16 -16 -16
Cash Interest Paid		 7.05 6.94 6.18 6.41 6.86 7.00 8.15 8.14 6.37 6.21

Annual Balance Sheets for Global Medical REIT

This table presents Global Medical REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 1,256 1,268 1,393
Cash and Due from Banks		 6.82 1.28 4.02
Restricted Cash		 2.13 5.45 10
Interest Bearing Deposits at Other Banks		 0.71 0.67 7.83
Trading Account Securities		 19 25 35
Loans and Leases, Net of Allowance		 0.00 0.00 0.00
Premises and Equipment, Net		 953 974 1,072
Deferred Acquisition Cost		 28 27 30
Goodwill		 5.90 5.90 5.90
Intangible Assets		 139 139 148
Other Assets		 102 89 81
Total Liabilities & Shareholders' Equity		 1,256 1,268 1,393
Total Liabilities		 701 662 744
Non-Interest Bearing Deposits		 3.32 3.69 5.46
Short-Term Debt		 632 585 636
Other Short-Term Payables		 33 29 30
Long-Term Debt		 14 26 58
Other Long-Term Liabilities		 18 18 15
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 556 606 649
Total Preferred & Common Equity		 534 584 633
Preferred Stock		 75 75 75
Total Common Equity		 459 509 558
Common Stock		 734 722 722
Retained Earnings		 -294 -239 -199
Accumulated Other Comprehensive Income / (Loss)		 19 25 35
Noncontrolling Interest		 22 22 16

Quarterly Balance Sheets for Global Medical REIT

This table presents Global Medical REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,243 1,241 1,264 1,303 1,321 1,369 1,407
Cash and Due from Banks		 5.72 4.98 1.33 1.28 2.46 4.60 3.20
Restricted Cash		 2.07 2.84 6.47 6.33 7.33 9.38 10
Interest Bearing Deposits at Other Banks		 1.69 0.93 0.74 9.86 9.73 8.63 7.66
Trading Account Securities		 15 28 29 38 36 27 37
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 948 941 960 988 1,007 1,053 1,087
Deferred Acquisition Cost		 28 28 28 27 26 30 29
Goodwill		 5.90 5.90 5.90 5.90 5.90 5.90 5.90
Intangible Assets		 138 136 139 139 140 148 148
Other Assets		 98 93 93 87 86 81 78
Total Liabilities & Shareholders' Equity		 1,243 1,241 1,264 1,303 1,321 1,369 1,407
Total Liabilities		 678 663 666 669 679 741 742
Non-Interest Bearing Deposits		 3.22 3.97 4.38 3.91 4.21 4.69 5.40
Short-Term Debt		 614 599 592 561 568 635 635
Other Short-Term Payables		 30 28 27 29 32 28 29
Long-Term Debt		 14 15 26 57 57 57 58
Other Long-Term Liabilities		 16 17 18 18 19 15 15
Total Equity & Noncontrolling Interests		 565 578 597 634 641 628 665
Total Preferred & Common Equity		 543 556 575 611 620 613 649
Preferred Stock		 75 75 75 75 75 75 75
Total Common Equity		 468 481 500 536 545 538 574
Common Stock		 734 723 723 722 722 722 722
Retained Earnings		 -281 -269 -252 -224 -214 -212 -185
Accumulated Other Comprehensive Income / (Loss)		 15 28 29 38 36 27 37
Noncontrolling Interest		 22 22 22 22 22 16 16

Annual Metrics And Ratios for Global Medical REIT

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 -0.06% -1.69% 16.43%
EBITDA Growth		 -8.62% -6.40% 9.83%
EBIT Growth		 -40.32% -46.82% -23.33%
NOPAT Growth		 -40.32% -46.82% -23.33%
Net Income Growth		 -69.21% 8.69% 9.02%
EPS Growth		 -95.65% 15.00% 5.26%
Operating Cash Flow Growth		 2.35% -10.58% 10.98%
Free Cash Flow Firm Growth		 -85.58% 218.02% 17.87%
Invested Capital Growth		 -1.23% -9.39% 10.36%
Revenue Q/Q Growth		 1.48% -2.01% 7.41%
EBITDA Q/Q Growth		 -4.68% -2.00% 7.45%
EBIT Q/Q Growth		 -37.57% -5.73% 22.69%
NOPAT Q/Q Growth		 -37.57% -5.73% -16.26%
Net Income Q/Q Growth		 55.48% -5.63% -15.40%
EPS Q/Q Growth		 150.00% -8.00% -20.00%
Operating Cash Flow Q/Q Growth		 3.54% -0.27% 1.36%
Free Cash Flow Firm Q/Q Growth		 -70.23% 17.22% 28.01%
Invested Capital Q/Q Growth		 0.72% -2.73% -1.05%
Profitability Metrics		 - - -
EBITDA Margin		 56.80% 62.12% 65.24%
EBIT Margin		 3.82% 6.39% 11.82%
Profit (Net Income) Margin		 6.08% 19.73% 17.85%
Tax Burden Percent		 159.22% 308.63% 150.99%
Interest Burden Percent		 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.35% 0.55% 1.03%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.74% 2.80% 2.09%
Return on Net Nonoperating Assets (RNNOA)		 0.80% 2.91% 2.07%
Return on Equity (ROE)		 1.15% 3.46% 3.11%
Cash Return on Invested Capital (CROIC)		 1.59% 10.40% -8.82%
Operating Return on Assets (OROA)		 0.33% 0.53% 1.00%
Return on Assets (ROA)		 0.53% 1.63% 1.51%
Return on Common Equity (ROCE)		 0.96% 2.94% 2.67%
Return on Equity Simple (ROE_SIMPLE)		 1.25% 3.72% 3.16%
Net Operating Profit after Tax (NOPAT)		 4.20 7.04 13
NOPAT Margin		 3.82% 6.39% 11.82%
Net Nonoperating Expense Percent (NNEP)		 -0.40% -2.25% -1.06%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 96.18% 93.61% 88.18%
Earnings before Interest and Taxes (EBIT)		 4.20 7.04 13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 63 68 73
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.12 1.30 0.93
Price to Tangible Book Value (P/TBV)		 1.64 1.82 1.28
Price to Revenue (P/Rev)		 4.68 6.01 4.62
Price to Earnings (P/E)		 635.91 44.77 38.84
Dividend Yield		 10.88% 8.32% 10.64%
Earnings Yield		 0.16% 2.23% 2.57%
Enterprise Value to Invested Capital (EV/IC)		 1.04 1.12 0.95
Enterprise Value to Revenue (EV/Rev)		 11.34 12.38 11.43
Enterprise Value to EBITDA (EV/EBITDA)		 19.97 19.92 17.51
Enterprise Value to EBIT (EV/EBIT)		 297.16 193.58 96.67
Enterprise Value to NOPAT (EV/NOPAT)		 297.16 193.58 96.67
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.83 19.92 16.73
Enterprise Value to Free Cash Flow (EV/FCFF)		 65.04 10.24 0.00
Leverage & Solvency		 - - -
Debt to Equity		 1.16 1.01 1.07
Long-Term Debt to Equity		 0.03 0.04 0.09
Financial Leverage		 1.08 1.04 0.99
Leverage Ratio		 2.17 2.12 2.06
Compound Leverage Factor		 2.17 2.12 2.06
Debt to Total Capital		 53.75% 50.22% 51.68%
Short-Term Debt to Total Capital		 52.55% 48.09% 47.38%
Long-Term Debt to Total Capital		 1.20% 2.13% 4.29%
Preferred Equity to Total Capital		 6.24% 6.16% 5.58%
Noncontrolling Interests to Total Capital		 1.81% 1.83% 1.20%
Common Equity to Total Capital		 38.20% 41.79% 41.54%
Debt to EBITDA		 10.33 8.93 9.49
Net Debt to EBITDA		 10.18 8.82 9.19
Long-Term Debt to EBITDA		 0.23 0.38 0.79
Debt to NOPAT		 153.73 86.80 52.41
Net Debt to NOPAT		 151.43 85.75 50.73
Long-Term Debt to NOPAT		 3.43 3.68 4.35
Noncontrolling Interest Sharing Ratio		 16.69% 15.00% 14.05%
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 19 133 -113
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.67 4.31 -4.47
Operating Cash Flow to Interest Expense		 2.44 2.22 3.03
Operating Cash Flow Less CapEx to Interest Expense		 2.44 2.22 3.03
Efficiency Ratios		 - - -
Asset Turnover		 0.09 0.08 0.08
Fixed Asset Turnover		 0.11 0.11 0.11
Capital & Investment Metrics		 - - -
Invested Capital		 1,202 1,217 1,343
Invested Capital Turnover		 0.09 0.09 0.09
Increase / (Decrease) in Invested Capital		 -15 -126 126
Enterprise Value (EV)		 1,249 1,363 1,280
Market Capitalization		 516 662 517
Book Value per Share		 $6.87 $7.76 $8.52
Tangible Book Value per Share		 $4.71 $5.55 $6.17
Total Capital		 1,202 1,217 1,343
Total Debt		 646 611 694
Total Long-Term Debt		 14 26 58
Net Debt		 636 604 672
Capital Expenditures (CapEx)		 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -2.49 -15 -6.75
Net Nonoperating Obligations (NNO)		 646 611 694
Total Depreciation and Amortization (D&A)		 58 61 60
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.01 $0.23 $0.20
Adjusted Weighted Average Basic Shares Outstanding		 65.94M 65.55M 65.46M
Adjusted Diluted Earnings per Share		 $0.01 $0.23 $0.20
Adjusted Weighted Average Diluted Shares Outstanding		 65.94M 65.55M 65.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.87M 65.57M 65.53M
Normalized Net Operating Profit after Tax (NOPAT)		 3.05 4.96 9.52
Normalized NOPAT Margin		 2.77% 4.50% 8.49%
Pre Tax Income Margin		 3.82% 6.39% 11.82%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.15 0.23 0.52
NOPAT to Interest Expense		 0.15 0.23 0.52
EBIT Less CapEx to Interest Expense		 0.15 0.23 0.52
NOPAT Less CapEx to Interest Expense		 0.15 0.23 0.52
Payout Ratios		 - - -
Dividend Payout Ratio		 981.62% 298.37% 321.27%
Augmented Payout Ratio		 981.62% 298.37% 321.27%

Quarterly Metrics And Ratios for Global Medical REIT

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 6.19% -4.62% -2.27% 0.96% -8.01% -0.37% -1.46% 3.27% 37.66% 13.08%
EBITDA Growth		 -18.72% -8.93% -5.38% -1.97% -7.83% -5.15% -8.70% -3.91% 39.75% 2.57%
EBIT Growth		 -178.22% -38.36% 2.88% 37.09% -23.17% -22.34% -63.72% -60.62% 406.81% -38.97%
NOPAT Growth		 -154.76% -38.36% 2.88% 37.09% -23.17% -22.34% -63.72% -60.62% -58.19% -38.97%
Net Income Growth		 433.39% -29.84% -113.77% 6.49% -70.17% -51.81% 269.77% -49.30% -66.34% 86.83%
EPS Growth		 300.00% -40.00% -127.78% 0.00% -200.00% -58.33% 500.00% -75.00% -83.33% 100.00%
Operating Cash Flow Growth		 13.23% -2.18% 5.87% -9.37% -1.00% -9.00% -23.87% -4.05% 5.93% -1.58%
Free Cash Flow Firm Growth		 -88.85% -45.40% 73.77% 237.84% 202.67% 164.20% 127.14% 49.54% 17.31% 11.53%
Invested Capital Growth		 -1.23% -4.62% -5.88% -8.01% -9.39% -7.82% -3.23% 6.46% 10.36% 14.57%
Revenue Q/Q Growth		 2.06% -0.81% -3.47% 8.67% -8.33% 1.63% -0.27% -1.00% -0.71% 0.52%
EBITDA Q/Q Growth		 -16.32% -1.17% -5.65% 4.18% -6.24% 2.68% -2.26% -2.04% -3.52% -1.16%
EBIT Q/Q Growth		 -170.79% 9.57% -38.16% 63.07% -44.22% 82.89% -17.59% -8.61% -43.62% -14.55%
NOPAT Q/Q Growth		 -149.55% 9.57% -38.16% 63.07% -44.22% 82.89% -17.59% -8.61% -43.62% -14.55%
Net Income Q/Q Growth		 -13.33% 273.72% -184.36% 319.96% -88.60% -65.91% 552.42% 17.65% -81.58% 161.58%
EPS Q/Q Growth		 -33.33% 160.00% -600.00% 200.00% -120.00% -72.22% 1,700.00% 0.00% -91.67% 300.00%
Operating Cash Flow Q/Q Growth		 25.89% -13.87% 32.43% -21.14% 8.75% -6.78% 13.36% -13.86% -0.03% -22.01%
Free Cash Flow Firm Q/Q Growth		 -76.03% -21.81% -29.79% -15.26% 17.36% 148.87% 155.69% 36.88% 26.61% -5.20%
Invested Capital Q/Q Growth		 0.72% 0.12% -1.88% -0.18% -2.73% -1.20% -4.10% -1.68% -1.05% 3.71%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 48.37% 59.00% 59.22% 60.59% 63.20% 61.79% 61.16% 62.40% 63.07% 64.91%
EBIT Margin		 -4.02% 5.80% 5.25% 8.20% 5.46% 8.98% 4.99% 6.04% 6.54% 11.52%
Profit (Net Income) Margin		 10.65% 12.55% -7.16% 8.20% 2.12% 17.06% 50.84% 7.77% 6.54% 35.26%
Tax Burden Percent		 -264.77% 216.26% -136.41% 100.00% 38.83% 189.98% 1,019.19% 128.73% 100.00% 306.14%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -0.26% 0.51% 0.47% 0.71% 0.47% 0.77% 0.44% 0.53% 0.57% 0.95%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.33% 0.81% -0.08% 0.71% 0.34% 1.12% 2.43% 0.61% 0.57% 2.03%
Return on Net Nonoperating Assets (RNNOA)		 0.36% 0.84% -0.08% 0.76% 0.35% 1.13% 2.42% 0.61% 0.57% 1.95%
Return on Equity (ROE)		 0.11% 1.35% 0.39% 1.48% 0.82% 1.91% 2.85% 1.14% 1.14% 2.90%
Cash Return on Invested Capital (CROIC)		 1.59% 5.28% 6.68% 8.95% 10.40% 8.71% 3.92% -5.42% -8.82% -12.33%
Operating Return on Assets (OROA)		 -0.35% 0.49% 0.45% 0.69% 0.45% 0.75% 0.42% 0.51% 0.55% 0.91%
Return on Assets (ROA)		 0.93% 1.07% -0.61% 0.69% 0.18% 1.42% 4.27% 0.66% 0.55% 2.78%
Return on Common Equity (ROCE)		 0.09% 1.14% 0.33% 1.25% 0.70% 1.63% 2.44% 0.98% 0.98% 2.50%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.79% 1.03% 3.80% 0.00% 3.77% 4.56% 2.92% 0.00% 3.64%
Net Operating Profit after Tax (NOPAT)		 -0.78 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
NOPAT Margin		 -2.82% 5.80% 5.25% 8.20% 5.46% 8.98% 4.99% 6.04% 6.54% 11.52%
Net Nonoperating Expense Percent (NNEP)		 -0.59% -0.29% 0.55% 0.00% 0.13% -0.35% -1.99% -0.08% 0.00% -1.08%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 104.02% 94.20% 94.75% 91.80% 94.54% 91.02% 95.01% 93.96% 93.46% 88.48%
Earnings before Interest and Taxes (EBIT)		 -1.11 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 13 16 16 17 16 18 17 17 18 18
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.12 1.39 1.24 1.12 1.30 1.01 1.01 0.99 0.93 0.83
Price to Tangible Book Value (P/TBV)		 1.64 2.01 1.76 1.58 1.82 1.38 1.37 1.39 1.28 1.14
Price to Revenue (P/Rev)		 4.68 5.99 5.42 5.08 6.01 4.80 4.87 4.73 4.62 4.57
Price to Earnings (P/E)		 635.91 0.00 0.00 37.61 44.77 33.73 26.21 47.19 38.84 28.46
Dividend Yield		 10.88% 8.48% 9.25% 9.82% 8.32% 10.21% 10.04% 10.29% 10.64% 11.47%
Earnings Yield		 0.16% 0.00% 0.00% 2.66% 2.23% 2.96% 3.82% 2.12% 2.57% 3.51%
Enterprise Value to Invested Capital (EV/IC)		 1.04 1.14 1.09 1.04 1.12 0.99 0.99 0.98 0.95 0.91
Enterprise Value to Revenue (EV/Rev)		 11.34 12.60 11.82 11.47 12.38 11.00 11.11 11.47 11.43 11.88
Enterprise Value to EBITDA (EV/EBITDA)		 19.97 20.83 19.32 18.61 19.92 17.72 17.67 17.89 17.51 18.21
Enterprise Value to EBIT (EV/EBIT)		 297.16 202.97 168.31 165.24 193.58 165.58 152.47 121.65 96.67 114.82
Enterprise Value to NOPAT (EV/NOPAT)		 297.16 202.97 168.31 165.24 193.58 165.58 152.47 121.65 96.67 78.37
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.83 20.20 19.08 18.92 19.92 18.02 17.80 17.07 16.73 16.41
Enterprise Value to Free Cash Flow (EV/FCFF)		 65.04 21.18 15.79 11.17 10.24 10.89 24.77 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.16 1.11 1.06 1.03 1.01 0.97 0.97 1.10 1.07 1.04
Long-Term Debt to Equity		 0.03 0.03 0.03 0.04 0.04 0.09 0.09 0.09 0.09 0.09
Financial Leverage		 1.08 1.04 1.02 1.07 1.04 1.01 1.00 1.00 0.99 0.96
Leverage Ratio		 2.17 2.12 2.10 2.15 2.12 2.09 2.08 2.07 2.06 2.05
Compound Leverage Factor		 2.17 2.12 2.10 2.15 2.12 2.09 2.08 2.07 2.06 2.05
Debt to Total Capital		 53.75% 52.69% 51.48% 50.85% 50.22% 49.36% 49.36% 52.41% 51.68% 51.04%
Short-Term Debt to Total Capital		 52.55% 51.48% 50.25% 48.74% 48.09% 44.82% 44.85% 48.07% 47.38% 46.77%
Long-Term Debt to Total Capital		 1.20% 1.21% 1.23% 2.11% 2.13% 4.54% 4.51% 4.34% 4.29% 4.27%
Preferred Equity to Total Capital		 6.24% 6.28% 6.29% 6.17% 6.16% 5.99% 5.92% 5.68% 5.58% 5.52%
Noncontrolling Interests to Total Capital		 1.81% 1.85% 1.84% 1.82% 1.83% 1.77% 1.72% 1.19% 1.20% 1.17%
Common Equity to Total Capital		 38.20% 39.18% 40.39% 41.16% 41.79% 42.88% 43.00% 40.72% 41.54% 42.27%
Debt to EBITDA		 10.33 9.59 9.14 9.07 8.93 8.85 8.83 9.56 9.49 10.18
Net Debt to EBITDA		 10.18 9.44 9.01 8.95 8.82 8.60 8.56 9.25 9.19 9.87
Long-Term Debt to EBITDA		 0.23 0.22 0.22 0.38 0.38 0.81 0.81 0.79 0.79 0.85
Debt to NOPAT		 153.73 93.42 79.61 80.56 86.80 82.68 76.21 65.02 52.41 43.81
Net Debt to NOPAT		 151.43 92.01 78.48 79.45 85.75 80.34 73.84 62.90 50.73 42.47
Long-Term Debt to NOPAT		 3.43 2.15 1.90 3.35 3.68 7.61 6.96 5.39 4.35 3.66
Noncontrolling Interest Sharing Ratio		 16.69% 16.20% 15.88% 15.32% 15.00% 14.48% 14.48% 14.07% 14.05% 13.93%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 14 59 76 108 128 109 44 -78 -124 -169
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 1.88 8.20 10.85 15.69 18.26 15.16 5.16 -9.48 -15.41 -24.31
Operating Cash Flow to Interest Expense		 2.71 2.25 2.71 2.07 2.60 2.32 2.11 1.91 2.27 2.63
Operating Cash Flow Less CapEx to Interest Expense		 2.71 2.25 2.71 2.07 2.60 2.32 2.11 1.91 2.27 2.63
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.09 0.09 0.09 0.08 0.08 0.08 0.08 0.09 0.08 0.08
Fixed Asset Turnover		 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.10
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 1,202 1,193 1,192 1,215 1,217 1,251 1,267 1,321 1,343 1,357
Invested Capital Turnover		 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.08
Increase / (Decrease) in Invested Capital		 -15 -58 -74 -106 -126 -106 -42 80 126 173
Enterprise Value (EV)		 1,249 1,366 1,297 1,267 1,363 1,237 1,251 1,295 1,280 1,239
Market Capitalization		 516 650 596 561 662 540 548 535 517 477
Book Value per Share		 $6.87 $7.13 $7.34 $7.63 $7.76 $8.18 $8.31 $8.21 $8.52 $8.76
Tangible Book Value per Share		 $4.71 $4.94 $5.17 $5.42 $5.55 $5.98 $6.09 $5.85 $6.17 $6.41
Total Capital		 1,202 1,193 1,192 1,215 1,217 1,251 1,267 1,321 1,343 1,357
Total Debt		 646 629 614 618 611 618 625 692 694 693
Total Long-Term Debt		 14 14 15 26 26 57 57 57 58 58
Net Debt		 636 619 605 609 604 600 606 670 672 672
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -3.72 -1.82 3.38 0.00 0.87 -2.29 -13 -0.49 0.00 -6.75
Net Nonoperating Obligations (NNO)		 646 629 614 618 611 618 625 692 694 693
Total Depreciation and Amortization (D&A)		 14 14 15 15 15 15 16 16 16 15
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Adjusted Weighted Average Basic Shares Outstanding		 65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Adjusted Diluted Earnings per Share		 $0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Adjusted Weighted Average Diluted Shares Outstanding		 65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.87M 66.80M 65.59M 65.59M 65.57M 65.56M 65.56M 65.53M 65.53M 65.52M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.67 1.10 1.00 1.62 0.99 1.78 0.98 1.21 1.37 2.37
Normalized NOPAT Margin		 -2.42% 4.06% 3.68% 5.74% 3.82% 6.28% 3.50% 4.33% 4.86% 8.34%
Pre Tax Income Margin		 -4.02% 5.80% 5.25% 8.20% 5.46% 8.98% 4.99% 6.04% 6.54% 11.52%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -0.15 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
NOPAT to Interest Expense		 -0.10 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
EBIT Less CapEx to Interest Expense		 -0.15 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
NOPAT Less CapEx to Interest Expense		 -0.10 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 981.62% 1,519.49% 1,136.55% 297.57% 298.37% 280.81% 228.49% 360.20% 321.27% 268.92%
Augmented Payout Ratio		 981.62% 1,519.49% 1,136.55% 297.57% 298.37% 280.81% 228.49% 360.20% 321.27% 268.92%

Frequently Asked Questions About Global Medical REIT's Financials

When does Global Medical REIT's financial year end?

According to the most recent income statement we have on file, Global Medical REIT's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Global Medical REIT's net income changed over the last 2 years?

Global Medical REIT's net income appears to be on a downward trend, with a most recent value of $6.69 million in 2024, falling from $20.00 million in 2022. The previous period was $21.73 million in 2023. See where experts think Global Medical REIT is headed by visiting Global Medical REIT's forecast page.

How has Global Medical REIT revenue changed over the last 2 years?

Over the last 2 years, Global Medical REIT's total revenue changed from $112.05 million in 2022 to $110.09 million in 2024, a change of -1.8%.

How much debt does Global Medical REIT have?

Global Medical REIT's total liabilities were at $700.57 million at the end of 2024, a 5.8% increase from 2023, and a 5.9% decrease since 2022.

How much cash does Global Medical REIT have?

In the past 2 years, Global Medical REIT's cash and equivalents has ranged from $1.28 million in 2023 to $6.82 million in 2024, and is currently $6.82 million as of their latest financial filing in 2024.

How has Global Medical REIT's book value per share changed over the last 2 years?

Over the last 2 years, Global Medical REIT's book value per share changed from 8.52 in 2022 to 6.87 in 2024, a change of -19.3%.


Related Companies

This page (NYSE:GMRE) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored